Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling

Overview of attention for article published in Molecular Cancer Therapeutics, July 2006

Altmetric Badge

Mentioned by

patent: 59 patents

Readers on

mendeley: 19 Mendeley
citeulike: 1 CiteULike

Summary Patents

So far, Altmetric has seen 59 patents that reference this research output.

Dosage regimes for the administration of an anti-CD19 ADC

Grant US-11938192-B2

United States of America

26 Mar 2024

Pyrrolobenzodiazepine-antibody conjugates

Grant US-11813335-B2

United States of America

14 Nov 2023

Pyrrolobenzodiazepine-antibody conjugates

Grant US-11779650-B2

United States of America

10 Oct 2023

Pyrrolobenzodiazepine-antibody conjugates

Grant US-11771775-B2

United States of America

03 Oct 2023

Site-specific antibody-drug conjugates

Grant US-11702473-B2

United States of America

18 Jul 2023

Pyrrolobenzodiazepines and conjugates thereof

Grant US-11701430-B2

United States of America

18 Jul 2023

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

Grant US-11690918-B2

United States of America

04 Jul 2023

Pyrrolobenzodiazepine conjugates

Grant US-11649250-B2

United States of America

16 May 2023

Pyrrolobenzodiazepine antibody conjugates

Grant US-11638760-B2

United States of America

02 May 2023

Pyrrolobenzodiazepine-antibody conjugates

Grant US-11612665-B2

United States of America

28 Mar 2023

Pyrrolobenzodiazepines and conjugates thereof as antitumour agents

Grant US-11524969-B2

United States of America

13 Dec 2022

Pyrrolobenzodiazepine antibody conjugates

Grant US-11517626-B2

United States of America

06 Dec 2022

Pyrrolobenzodiazepine conjugates

Grant US-11370801-B2

United States of America

28 Jun 2022

Methods

Grant US-11352324-B2

United States of America

07 Jun 2022

Dosage regimes for the administration of an anti-CD19 ADC

Grant US-11318211-B2

United States of America

03 May 2022

Pyrrolobenzodiazepine-antibody conjugates

Grant US-11160872-B2

United States of America

02 Nov 2021

Humanized anti-AXL antibodies

Grant US-11059893-B2

United States of America

13 Jul 2021

Pyrrolobenzodiazepines and conjugates thereof

Grant US-10994023-B2

United States of America

04 May 2021

Pyrrolobenzodiazepine-antibody conjugates

Grant US-10799596-B2

United States of America

13 Oct 2020

Pyrrolobenzodiazepine conjugates

Grant US-10799595-B2

United States of America

13 Oct 2020

Pyrrolobenzodiazepine-antibody conjugates

Grant US-10780096-B2

United States of America

22 Sep 2020

Pyrrolobenzodiazepine-antibody conjugates

Grant US-10780181-B2

United States of America

22 Sep 2020

Pyrrolobenzodiazepine—anti-PSMA antibody conjugates

Grant US-10751346-B2

United States of America

25 Aug 2020

Pyrrolobenzodiazepine-anti-PSMA antibody conjugates

Grant US-10736903-B2

United States of America

11 Aug 2020

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

Grant US-10722594-B2

United States of America

28 Jul 2020

Pyrrolobenzodiazepine-antibody conjugates

Grant US-10695433-B2

United States of America

30 Jun 2020

Pyrrolobenzodiazepine conjugates

Grant US-10695439-B2

United States of America

30 Jun 2020

Pyrrolobenzodiazepines and conjugates thereof

Grant US-10646584-B2

United States of America

12 May 2020

Targeted pyrrolobenzodiazapine conjugates

Grant US-10561739-B2

United States of America

18 Feb 2020

Combination therapy with an anti-axl antibody-drug conjugate

Grant US-10544223-B2

United States of America

28 Jan 2020

Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer

Grant US-10543279-B2

United States of America

28 Jan 2020

Pyrrolobenzodiazepines and conjugates thereof

Grant US-10420777-B2

United States of America

24 Sep 2019

Pyrrolobenzodiazepines

Grant US-10392393-B2

United States of America

27 Aug 2019

Pyrrolobenzodiazepines and conjugates thereof

Grant US-10335497-B2

United States of America

02 Jul 2019

Pyrrolobenzodiazepines and targeted conjugates

Application US-10328084-B2

United States of America

25 Jun 2019

Pyrrolobenzodiazepines and targeted conjugates

Grant US-10329352-B2

United States of America

25 Jun 2019

Pyrrolobenzodiazepines and conjugates thereof

Grant US-10029018-B2

United States of America

24 Jul 2018

Pyrrolobenzodiazepine-antibody conjugates

Grant US-10010624-B2

United States of America

03 Jul 2018

Pyrrolobenzodiazepine—antibody conjugates

Grant US-9956299-B2

United States of America

01 May 2018

Pyrrolobenzodiazepines and conjugates thereof

Grant US-9956298-B2

United States of America

01 May 2018

Pyrrolobenzodiazepine-antibody conjugates

Grant US-9950078-B2

United States of America

24 Apr 2018

Pyrrolobenzodiazepine-antibody conjugates

Grant US-9931415-B2

United States of America

03 Apr 2018

Pyrrolobenzodiazepine-antibody conjugates

Grant US-9931414-B2

United States of America

03 Apr 2018

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

Grant US-9919056-B2

United States of America

20 Mar 2018

Pyrrolobenzodiazepines and conjugates thereof

Grant US-9889207-B2

United States of America

13 Feb 2018

Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation

Grant US-9745303-B2

United States of America

29 Aug 2017

Pyrrolobenzodiazepines used to treat proliferative diseases

Application US-9732084-B2

United States of America

15 Aug 2017

Pyrrolobenzodiazepines and targeted conjugates

Application US-9713647-B2

United States of America

25 Jul 2017

Pyrrolobenzodiazepines and targeted conjugates

Application US-9707301-B2

United States of America

18 Jul 2017

Targeted pyrrolobenzodiazapine conjugates

Grant US-9592240-B2

United States of America

14 Mar 2017

Pyrrolobenzodiazepines and targeted conjugates

Grant US-9526798-B2

United States of America

27 Dec 2016

Pyrrolobenzodiazepines and conjugates thereof

Grant US-9415117-B2

United States of America

16 Aug 2016

Pyrrolobenzodiazepines

Application US-9399073-B2

United States of America

26 Jul 2016

Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted…

Application US-9399641-B2

United States of America

26 Jul 2016

Pyrrolobenzodiazepines

Grant US-9388187-B2

United States of America

12 Jul 2016

Pyrrolobenzodiazepines and targeted conjugates

Grant US-9387259-B2

United States of America

12 Jul 2016

Targeted pyrrolobenzodiazapine conjugates

Grant US-9242013-B2

United States of America

26 Jan 2016

PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES

Application US-20140286970-A1

United States of America

25 Sep 2014

Pyrrolobenzodiazepines used to treat proliferative diseases

Application US-8697688-B2

United States of America

15 Apr 2014

American Association for Cancer Research

Article Metrics

Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling

Mentioned by

Readers on

Dosage regimes for the administration of an anti-CD19 ADC

Grant US-11938192-B2

United States of America

Pyrrolobenzodiazepine-antibody conjugates

Grant US-11813335-B2

United States of America

Pyrrolobenzodiazepine-antibody conjugates

Grant US-11779650-B2

United States of America

Pyrrolobenzodiazepine-antibody conjugates

Grant US-11771775-B2

United States of America

Site-specific antibody-drug conjugates

Grant US-11702473-B2

United States of America

Pyrrolobenzodiazepines and conjugates thereof

Grant US-11701430-B2

United States of America

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

Grant US-11690918-B2

United States of America

Pyrrolobenzodiazepine conjugates

Grant US-11649250-B2

United States of America

Pyrrolobenzodiazepine antibody conjugates

Grant US-11638760-B2

United States of America

Pyrrolobenzodiazepine-antibody conjugates

Grant US-11612665-B2

United States of America

Pyrrolobenzodiazepines and conjugates thereof as antitumour agents

Grant US-11524969-B2

United States of America

Pyrrolobenzodiazepine antibody conjugates

Grant US-11517626-B2

United States of America

Pyrrolobenzodiazepine conjugates

Grant US-11370801-B2

United States of America

Methods

Grant US-11352324-B2

United States of America

Dosage regimes for the administration of an anti-CD19 ADC

Grant US-11318211-B2

United States of America

Pyrrolobenzodiazepine-antibody conjugates

Grant US-11160872-B2

United States of America

Humanized anti-AXL antibodies

Grant US-11059893-B2

United States of America

Pyrrolobenzodiazepines and conjugates thereof

Grant US-10994023-B2

United States of America

Pyrrolobenzodiazepine-antibody conjugates

Grant US-10799596-B2

United States of America

Pyrrolobenzodiazepine conjugates

Grant US-10799595-B2

United States of America

Pyrrolobenzodiazepine-antibody conjugates

Grant US-10780096-B2

United States of America

Pyrrolobenzodiazepine-antibody conjugates

Grant US-10780181-B2

United States of America

Pyrrolobenzodiazepine—anti-PSMA antibody conjugates

Grant US-10751346-B2

United States of America

Pyrrolobenzodiazepine-anti-PSMA antibody conjugates

Grant US-10736903-B2

United States of America

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

Grant US-10722594-B2

United States of America